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Mutations in the skeletal muscle channel (SCN4A), encoding the Nav1.4 voltage-gated sodium channel, are causative of a
variety of muscle channelopathies, including non-dystrophic myotonias and periodic paralysis. The effects of many of these
mutations on channel function have been characterized both in vitro and in vivo. However, little is known about the conse-
quences of SCN4A mutations downstream from their impact on the electrophysiology of the Nav1.4 channel. Here we report the
discovery of a novel SCN4A mutation (c.1762A4G; p.I588V) in a patient with myotonia and periodic paralysis, located within
the S1 segment of the second domain of the Nav1.4 channel. Using N-ethyl-N-nitrosourea mutagenesis, we generated and
characterized a mouse model (named draggen), carrying the equivalent point mutation (c.1744A4G; p.I582V) to that found in
the patient with periodic paralysis and myotonia. Draggen mice have myotonia and suffer from intermittent hind-limb immo-
bility attacks. In-depth characterization of draggen mice uncovered novel systemic metabolic abnormalities in Scn4a mouse
models and provided novel insights into disease mechanisms. We discovered metabolic alterations leading to lean mice, as well
as abnormal AMP-activated protein kinase activation, which were associated with the immobility attacks and may provide a
novel potential therapeutic target.
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The voltage-dependent sodium skeletal muscle -subunit Nav1.4
channel, encoded by the SCN4A gene, is responsible for the ini-
tiation and propagation of the action potential in the muscle ﬁbres
that results in muscle contraction. Other ion channels in muscle
ﬁbre membranes (potassium, calcium and chloride channels) con-
trol the resting membrane potential, the repolarization following
an action potential, and the Ca
2+ entry into the cytoplasm that
govern the contraction and the relaxation of the muscles. There
are many pathological mutations found in the SCN4A gene lead-
ing to changes in the electrophysiological properties of the Nav1.4
channel and in muscle ﬁbre excitability (Cannon, 1996a, 2006;
Webb and Cannon, 2008).
The Nav1.4 channel is a large protein composed of four hom-
ologous domains (I–IV), each with six transmembrane helices (S1–
S6). The majority of causative SCN4A mutations are missense,
gain of function mutations (Tsujino et al., 2003; Jurkat-Rott
et al., 2010; Lossin et al., 2012), and are usually located within
the pore forming segments S5–S6, the voltage sensor segment S4
or the S4–S5 linker of the Nav1.4 channel. There are a number of
clinically classiﬁed types of muscle channelopathies caused by mu-
tations in the SCN4A gene (Vicart et al., 2005), including: potas-
sium-aggravated myotonia, paramyotonia congenita,
hyperkalaemic periodic paralysis and hypokalaemic periodic paraly-
sis. The deﬁning features of SCN4A skeletal muscle channelopa-
thies are myotonia and/or muscle weakness (Fontaine et al., 1990;
Cannon, 1996b). Periodic paralysis is characterized by reduced
muscle membrane excitability, resulting in attacks of muscle weak-
ness (Fontaine et al., 1990; Rojas et al., 1991; McClatchey et al.,
1992). The attacks are often associated with increased (hyperka-
laemic periodic paralysis) or reduced (hypokalaemic periodic par-
alysis) serum potassium levels. Myotonia is in turn characterized by
increased muscle membrane excitability, leading to muscle stiffness
(Matthews et al., 2010). There is some overlap in the clinical
symptoms; for example patients diagnosed with hyperkalaemic
periodic paralysis and paramyotonia congenita can present with
attacks of both myotonia and paralysis. In a recent attempt to
categorize patients with hyperkalaemic periodic paralysis, three
clinical subgroups were proposed depending if patients presented
without myotonia, with clinical or EMG myotonia or with para-
myotonia congenita (Charles et al., 2013). In addition, the same
SCN4A mutation can be found in patients with different clinical
diagnosis (Sasaki et al., 1999; Okuda et al., 2001; Jurkat-Rott and
Lehmann-Horn, 2007). Overall, there is little known about the
consequences of SCN4A mutations in the muscle downstream of
their impact on the electrophysiology of the Nav1.4 channel.
In recent years two knock-in mouse models of periodic paralysis
have been generated to study the effects of Scn4a mutations on
skeletal muscle function. The ﬁrst Scn4a knock-in model carries
the mouse equivalent of the most common human hyperkalaemic
periodic paralysis mutation (M1592V) (Hayward et al., 2008).
Heterozygous mice develop myotonia and progressive myopathy,
together with ex vivo potassium-aggravated muscle weakness.
The other knock-in strain models hypokalaemic periodic paralysis
via another Scn4a mutation (R669H) (Wu et al., 2011). More
recently a Cacna1s knock-in model of periodic paralysis has
been developed (Wu et al., 2012).
Skeletal muscle is a major metabolic regulator where ATP
homeostasis is critical for its function. Conversely, pathological al-
terations in skeletal muscle can lead to a disruption in the whole
body metabolic balance (Pedersen and Febbraio, 2012). Muscles
convert the chemical energy of carbohydrates and fats ﬁrst into
chemical energy (ATP) and then into mechanical work and heat.
The use of energy in the form of ATP during muscle contraction
leads to an increase in the concentrations of AMP and ADP that in
turn activate AMP-activated protein kinase (AMPK) via phosphor-
ylation at its Thr172 residue (Hardie and Sakamoto, 2006). As a
consequence, active AMPK inhibits anabolic and activates cata-
bolic pathways to increase the rate and capacity of ATP produc-
tion (Winder and Hardie, 1996; O’Neill et al., 2013). AMPK
signalling is therefore regarded as a key regulator of energy
status in muscle ﬁbres. Ion channels control muscle contractile
activity and thus can affect ATP turnover in muscle ﬁbres.
AMPK activation has been reported to regulate ion channel activ-
ity directly (Evans et al., 2012) and indirectly (Light et al., 2003),
thus providing a link between cellular energy demands and ion
channel activity (Ingwersen et al., 2011; Andersen and
Rasmussen, 2012).
Here we report the identiﬁcation of a novel dominant SCN4A
mutation identiﬁed in a patient presenting with myotonia and
periodic paralysis. We also report the identiﬁcation of the mouse
equivalent of this mutation, which we named draggen, found in
an N-ethyl-N-nitrosurea (ENU) mutagenesis screen (Nolan et al.,
2002; Acevedo-Arozena et al., 2008). In-depth characterization of
draggen mice, a novel mouse model of myotonia and periodic
paralysis, found alterations in whole animal metabolism caused
by Scn4a mutations accompanied by inappropriate AMPK activa-
tion in mice.
Materials and methods
Ethics statement
Consent for all neurophysiological tests was obtained, with tests per-
formed as previously described (Fournier et al., 2004, 2006; Tan et al.,
2011). All animal studies were carried out in accordance with UK
Home Ofﬁce legislation and local ethical guidelines. Mice character-
ization followed ARRIVE guidelines.
Mice
Mice were kept under a controlled 12-h light cycle and had free access
to water and were fed ad libitum on a commercial diet (SDS).
Draggen mice were identiﬁed in the course of a dominant modiﬁer
ENU screen (Acevedo-Arozena et al., 2008). Brieﬂy, BALB/c male mice
were intraperitoneally injected twice with 100mg/kg ENU at 12 weeks
of age and crossed to congenic C57BL/6J females. An individual drag-
gen G1 founder showing intermittent hind-limb immobility or dragging
attacks was initially identiﬁed and subsequently backcrossed onto
C57BL/6J to assess inheritance. Affected individuals from the initial
backcross showing hind-limb dragging attacks were used for a
genome-wide scan that identiﬁed a critical region on mouse
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as a candidate gene and a missense mutation was subsequently iden-
tiﬁed by Sanger sequencing. Mice used in this study are at least N3
(three generations of backcross onto C57BL/6J); the colony is currently
on N8. The draggen ofﬁcial allele name is: Scn4a
m1Aaa. Scn4a
M1592V/+
[FVB.129S4(B6)-Scn4a
tm1.1Ljh/J] mice were purchased from Jackson
laboratories on a congenic FVB background and maintained by cross-
ing to C57BL/6J for comparison with draggen mice. Scn4a
M1592V/+
mice used were backcrossed to C57BL/6J for at least two generations.
All genotyping was performed by pyrosequencing (primer sequences
available on request).
Phenotyping tests
For phenotyping tests, see the online Supplementary material.
Dragging scoring
To quantify the age at onset and frequency of hind-limb immobility
attacks in mice, we established a scoring system in which all mice were
tested once a week from weaning until 60 weeks of age. It was
observed that immobility events in draggen mice were more often
seen on ﬁrst opening of the cage in the morning. Thus, in the early
morning, undisturbed mice were brieﬂy held by the tail and then left
to rear in their home cage. Hind-limb dragging was then recorded as
present or absent by a trained technician.
Electromyogram
EMGs were obtained from calf, hamstring, triceps and paraspinal mus-
cles with concentric needle electrodes in isoﬂurane anaesthetized male
mice at 30 weeks of age (n=5 per genotype). Young wild-type and
non-affected males at 8–9 weeks of age (n=4 per genotype), and 60-
week-old wild-type and non-hind-limb dragging females (n=4 per
genotype) were also evaluated.
For chronic EMG, three draggen male mice were implanted with a
wireless EMG system (Data Sciences F20-EET, Gold system). A trans-
mitter was surgically implanted through an incision on the back, with
leads from the transmitter leading, subcutaneously, to the right hind-
limb. Two electrodes for the EMGs were attached to the gastrocnemius
muscle. The surgeries were conducted with the mouse under ketamine–
xylanine anaesthesia. A post-surgery period of 1 week was given to
each mouse to ensure a full recovery. At the end of the recovery
period, we recorded the EMG signal uninterruptedly. Sampling rate
was 500Hz and data were processed using SleepSign software (Kissei
Comtec). The mice were singly housed and free to move in the cage.
We continuously acquired videos with a computer synchronized with
the EMG recordings. Videos were visually scored and immobility attacks
were identiﬁed by at least two independent observers.
Physiological assessment of muscle force and in vitro
electrophysiology analysis
For physiological assessment of muscle force and in vitro electrophysi-
ology analysis, see the online Supplementary material.
Histology
Young and adult male wild-type and draggen littermate (n=3) hind-
limb muscles (tibialis anterior, extensor digitorum longus, gastrocne-
mius and soleus) were dissected at stated ages, weighed and snap
frozen and 10-mm sections were cut in a cryostat. Tibialis anterior
sections were stained using haematoxylin and eosin (and NADH-tetra-
zolium reductase) and an antibody-based stain for myosin heavy chain
isoforms (IIa and IIb) as previously published (Bloemberg and
Quadrilatero, 2012), with Alexa Fluor 488 and 555 as secondary
antibodies. Fibre numbers were recorded using ImageJ software
(NIH). Fibre cross-sectional areas were measured for different ﬁbre
types (tibialis anterior, soleus) and ﬁbre count and type percentages
were assessed. For pups: post-natal Day 0 pups were sacriﬁced and
formalin ﬁxed. They were cut in longitudinal body halves and sections
were stained with haematoxylin and eosin.
Transmission electron microscopy
Mice were perfused with a mix of 2% glutaraldehyde and 2% paraf-
ormaldehyde in PBS. Hind-limb muscles were dissected and placed in
1% OsO4 on ice for 1h followed by two 5-min washes with phos-
phate buffer (100mM NaH2PO4/Na2HPO4.2H20). The samples were
dehydrated through an ethanol series (30%, 50%, 70%, 95% and
absolute) and transferred to a 1:1 mixture of Epon/Araldite and acet-
one and incubated overnight with mixing. The solution was then
replaced with a 1:1 mixture of 100% Epon/Araldite and incubated
for 6h, followed by another replacement with fresh Epon/Araldite
and overnight incubation with mixing. Samples were transferred to
fresh Epon/Araldite in embedding moulds and oriented as required.
Polymerization of the Epon/Araldite mould was completed at 65C
for 48h. Seventy nanometre sections were produced and stained
with saturated uranyl acetate and Reynolds’ lead citrate. All images
were obtained with a Tecnai 12 BioTWIN made by FEI.
Immuno-blot analysis
Primary antibodies against p-AMPK (Thr172) and total AMPK were
obtained from Cell Signalling. Tibialis anterior and extensor digitorum
longus muscles from draggen, M1592V and age-matched wild-type
littermate controls were homogenized in 10 volumes of RIPA buffer
(with phosphatase and protease inhibitor cocktails from Roche). After
spinning the homogenate at 12000g at 4C, the supernatant was used
for western blot analysis using pre-cast SDS gels (Invitrogen). The
Odyssey infrared imaging system (Li-Cor) was used for band detection
and quantiﬁcation.
Statistical analysis
Data is presented as the mean  standard error of the mean (SEM).
Comparisons between two groups were made using the two-tailed
Student’s t-test and Mann-Whitney. ANOVA with post hoc analysis
(Bonferroni and Tukey) was used as appropriate. For survival and age-
at-onset analysis, the Log-Rank test was performed. P-values were
determined by SPSS v.19 software. P40.05 was considered statistic-
ally signiﬁcant.
Results
A novel mutation in SCN4A leads to
myotonia and periodic paralysis
A novel SCN4A mutation was identiﬁed in a patient presenting
with myotonia and periodic paralysis. The mutation identiﬁed
(c.1762A4G;p.I588V, SCN4A
I588V) is located within the trans-
membrane S1 region of domain II. Mutations within this region
have not been previously identiﬁed as causative of myotonia or
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in the exome variant server, 1000 Genomes, Leiden Open
Variation Database or dbSNP. The 70-year-old male patient pre-
sented with a history of muscle stiffness and weakness from the
age of eight. The stiffness was worst in his calves and worsened
by exertion. The patient also noted episodes of weakness that
were precipitated by running which would persist for weeks
before complete resolution. In the past few years the episodes
of weakness became more frequent, severe and prolonged, occur-
ring once every 2–3 weeks. The episodes of stiffness have also
persisted, primarily occurring following rest after exertion, with no
reported sensitivity to cold. There is evidence of a family history
(Fig. 1A), with a severely affected younger brother, father and
paternal grandmother. The patient’s three daughters and two sis-
ters are reported to be unaffected but were unavailable for assess-
ment. Physical examination of the patient demonstrated myotonia
of the eyelids that did not worsen with exertion. The patient had
normal tone and power and reﬂexes throughout but some atrophy
of the calves was noted. Neurophysiological testing demonstrated
the presence of myotonia that worsened after the muscles were
cooled (data not shown). Short exercise testing was normal both
at room temperature and following cooling. In the long exercise
test there was a decrease in amplitude of 38% and a concordant
58% of the area of the compound muscle action potential from
baseline, which is abnormal (Tan et al., 2011) (Supplementary Fig.
1A). The history of episodic weakness and stiffness from childhood
alongside evidence of myotonia and a positive long exercise test
was consistent with a clinical diagnosis of hyperkalaemic periodic
paralysis together with paramyotonia congenita.
Generation of a novel mouse model
(draggen) carrying the equivalent point
mutation in Scn4a
Through an unbiased large-scale ENU mutagenesis screen for
dominant mutations (Nolan et al., 2000), we identiﬁed a mutant
mouse, named draggen (Dgn/+), with unprovoked intermittent
attacks of hind-limb dragging or immobility. After positional clon-
ing, a missense mutation in the mouse Scn4a gene was identiﬁed
in the critical region of mouse chromosome 11, which segregated
with the intermittent dragging phenotype. Once the mutation was
identiﬁed, the colony was subsequently maintained by genotyping,
with immobility attacks only affecting draggen mice. Remarkably,
the mutation identiﬁed (c.1744A4G; p.I582V or Scn4a
I582V) is the
mouse equivalent to the newly identiﬁed human SCN4A
I588V mu-
tation described above (Fig. 1B). The mutated isoleucine residue is
conserved between mice and humans and across species, and is
also conserved in all mouse and human sodium voltage-gated
channel paralogues (Supplementary Fig. 1B).
In vitro electrophysiological characteri-
zation of the novel SCN4A and Scn4a
mutations
To evaluate the electrophysiology of the novel Scn4a
I582V and
SCN4A
I588V mutations, HEK293 cells were transfected with
cDNA coding for the mouse or human wild-type or mutant
Nav1.4 channel. Channel properties were analysed using whole-
cell patch clamp. Voltage dependence of channel activation was
shifted 6mV in the hyperpolarizing direction in the mutant for
both mouse and human clones (P50.005, n=10–25) (Fig. 1C,
Supplementary Fig. 1C and Table 1), suggesting a gain of func-
tion. The voltage dependence of fast inactivation was shifted 3mV
in the hyperpolarizing direction for both mouse and human
mutant channels [P=0.06 for mouse clone (n=13–15),
P50.01 for human clone (n=18–20)] (Fig. 1C, Supplementary
Fig. 1C and Table 1). No signiﬁcant differences were detected in
the voltage dependence of slow inactivation (Fig. 1C,
Supplementary Fig. 1C and Table 1).
Myotonia and hind-limb immobility
attacks in draggen mice
Draggen mice (Scn4a
Dgn/+) suffered from unprovoked intermit-
tent hind-limb immobility attacks when the mouse was not able
to move the hind-limbs. This was followed by a total recovery in
mobility after a short period of time usually lasting a few seconds
(Supplementary Video 1). To systematically assess the hind-limb
dragging onset and frequency, mutant mice were subjected to a
test once a week from 3 weeks of age; hind-limb immobility at-
tacks were scored as present or absent. Through this process, a
clear difference in the penetrance of the observed intermittent
dragging phenotype was noted between male and female
mutant mice (Fig. 2A, P50.001). All males carrying the draggen
mutation showed at least one hind-limb immobility episode by 60
weeks of age (100% penetrance), with an average age at onset of
16 weeks of age. However, only 38% of draggen females dis-
played an episode at least once during the same period, with an
average age at onset of 25 weeks of age, which is signiﬁcantly
different from that observed in males (P=0.013). For those mice
showing the intermittent attacks, there is a large variation in the
age at which the ﬁrst attack is detected, with extreme cases show-
ing the ﬁrst episode as early as weaning (3 weeks of age) or as
late as 50–60 weeks of age. In addition, the frequency of hind-
limb dragging attacks that was observed over the lifetime of indi-
vidual mice was also different between males (average 8  0.9
episodes up to 60-weeks of age) and affected females
(2.6  0.4 episodes; P50.001).
As the proband presented with myotonia, draggen mice were
subjected to electromyography (EMG) of hind-limb muscles.
Mutant mice showed striking myotonic runs after light movement
of the needle that were not present in wild-type littermate con-
trols (Fig. 2B). Interestingly, myotonia was present in all of the
draggen mice assessed. These included young males tested before
their ﬁrst recorded dragging attack, as well as aged draggen fe-
males that never had any recorded hind-limb immobility event
(data not shown). Hence, myotonia is fully penetrant in draggen
mutants, including females that have never shown a dragging
episode based on our scoring system.
To study the muscle activity during the hind-limb immobility
attacks, we performed chronic, wireless EMG on freely moving
singly housed draggen males. We synchronized the EMG
3174 | Brain 2014: 137; 3171–3185 S. Corrochano et al.recordingswithvideomonitoringtofocusontheEMGactivityduring
the dragging events. The intermittent immobility attacks were
accompanied by high EMG activity, which continued throughout
the whole event (Fig. 2C and Supplementary Fig. 2). Overall, this
intense EMG activity suggests that the immobility or dragging at-
tacks are not produced by muscle weakness in draggen mice.
The draggen mutation is homozygous
lethal
Heterozygous draggen mice (Scn4a
Dgn/+) had a normal lifespan
up to 2 years of age (Supplementary Fig. 3A). However, although
homozygous draggen mice (Scn4a
Dgn/Dgn) are born at Mendelian
Figure 1 Mutations in SCN4A and Scn4a and functional characterization. (A) Family history of the c.1762A4G; I588V mutation.
Proband indicated by arrow, affected family members are shaded. Females represented by circles and males by quadrangles. (B) Sequence
trace showing the Scn4a c.1744A4G; p.I582V mutation in draggen mice. (C) Voltage dependence of activation (circles), fast inactivation
(squares) and slow inactivation (triangles) for human (h) wild-type (black) and I588V (red) hNav1.4 channels. The y-axis shows normalized
conductance (activation) or current (fast and slow inactivation). The lines through the data are the best ﬁt of the Boltzmann equation to
the data. Data and statistical analysis are represented in Table 1.
Table 1 Electrophysiological properties of wild-type and mutant Nav1.4 channels
Activation Fast inactivation Slow inactivation
Clone n V1/2 (mV) n V1/2 (mV) n V1/2 (mV) C (%)
hWT 25 18.8  0.7 20 65.9  0.7 15 52.8  1.4 9.8  1.1
I588V 21 24.8  0.6*** 18 68.9  0.8** 15 53.7  1.2 13.2  0.8
mWT 12 17.5  0.6 15 65.1  1.2 10 49.6  1.2 7.8  1.6
Draggen 10 23.1  1.1*** 13 68.5  1.2 5 52.5  3.4 10.5  3.0
Voltage values at which half of the channels (V1/2) were activated (Activation) or inactivated (fast and slow inactivation) and the offset current (C) of slow inactivation are
stated for human and mouse wild-type (hWT and mWT), human I588V and Draggen mouse (I582V) mutant channels. Statistical comparisons are between the wild-type
and mutant clones. **P50.01, ***P50.001.
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Dgn/Dgn from
a total of 90 pups born), we did not observe any homozygous
pups older than 2 days. Scn4a
Dgn/Dgn mice died perinatally with
noted breathing difﬁculties, conﬁrmed by the observation of col-
lapsed lungs (Supplementary Fig. 3B), but otherwise morphologic-
ally normal organs. Notably, skeletal muscle, including diaphragm,
was also morphologically normal (data not shown), suggesting
that the cause of death may be due to a functional impairment
of muscles required for breathing and suckling.
To conﬁrm that the homozygous lethality was due to the Scn4a
draggen mutation, an allelic complementation cross was per-
formed with a previously generated Scn4a knock-in mouse strain
(Scn4a
M1592V/+) (Hayward et al., 2008). Scn4a
Dgn/M1592V com-
pound mutant mice were born at Mendelian ratios (15
Scn4a
Dgn/M1592V out of 59 pups born) but also died perinatally
with similar difﬁculties in breathing and lung morphology
(Supplementary Fig. 3C). We therefore concluded that the lethal-
ity was due to Scn4a allelic non-complementation.
Reduced muscle force generated by
draggen muscles
Muscle force, measured by grip-strength (Supplementary Fig. 4A),
and motor coordination, measured as locotronic performance
(Supplementary Fig. 4B), progressively deteriorated in draggen
mice. To further assess muscle force in vivo, the physiology of
the hind-limb tibialis anterioris and extensor digitorum longus
muscles were studied in a cohort of wild-type and draggen male
littermates at 60 weeks of age. For both the tibialis anterior and
extensor digitorum longus muscles, the time at which maximum
contraction (Tmax) and half relaxation (T1/2R) were achieved was
signiﬁcantly higher in draggen mice compared to wild-type litter-
mates (Fig. 3A and B, P50.001 for all comparisons). Moreover,
the single twitch force (Fig. 3B) and the maximum force generated
by the extensor digitorum longus muscles (Fig. 3C) were lower in
draggen mice when compared with wild-type (P50.001 for all
comparisons). This was not due to a difference in tibialis anterior
and extensor digitorum longus muscles weight (data not shown).
Fast-twitch muscles, such as the extensor digitorum longus, nor-
mally fatigue rapidly and cannot maintain force when repeatedly
stimulated, whereas slow-twitch muscles are more resistant to fa-
tigue. Typical fatigue traces show that the extensor digitorum
longus of draggen mice becomes more fatigue-resistant after
stimulation (Fig. 3D). The fatigue index of draggen extensor digi-
torum longus muscles was almost double that of the wild-type
littermate controls (P50.001). This is usually observed in slow-
twitch muscles and muscles adapted to repeated contractile activ-
ity or endurance training, suggesting potential metabolic changes
Figure 2 Draggen mice suffer from immobility attacks and myotonia. (A) Age at onset of hind-limb immobility attacks of draggen males
and females up to 60 weeks of age. Males: n=65, females: n=46. Log-Rank comparison between overall males and females: P50.001.
All 65 males and 17 (38%) draggen females had at least one hind-limb dragging episode. Differences in age at onset between males and
females were detected when selecting dragging-affected females (P=0.013). (B). Electromyography traces representative of male wild-
type and draggen hind-limb muscles. Wild-type recording illustrates artefacts from multiple needle movements that failed to evoke
myotonic discharges in all wild-type mice whereas long myotonic runs were always elicited in draggen mice (n=5 mice per group). (C)
Chronic EMG recordings from the gastrocnemius muscle of a draggen male mouse before, during and after an intermittent immobility
event (named crisis). High EMG activity accompanies the hind-limb dragging episode (highlighted as ‘crisis’).
3176 | Brain 2014: 137; 3171–3185 S. Corrochano et al.Figure 3 Draggen mice have muscle weakness. In vivo physiological assessment of hind-limb muscles of 60-week-old male mice.
Scn4a
+/+ (n=12); Scn4a
Dgn/+ (n=14). (A) Tibialis anterior (TA) muscle force showed that the time to peak force (Tmax) and half-time
relaxation time (T1/2R) were signiﬁcantly longer in draggen mice than wild-type controls. For Tmax (Scn4a
+/+ = 17.5ms; Scn4a
+/+;
Scn4a
Dgn/+ = 21.9ms; P50.001). For T1/2R (Scn4a
+/+ = 13.3ms; Scn4a
Dgn/+ = 20.6ms; P50.001). Single twitch force for tibialis
anterior muscles was not signiﬁcantly different between wild-type and draggen muscles (Scn4a
+/+ = 54.1g; Scn4a
Dgn/+ = 45.7g;
P=0.19). The two traces shown per image represent the right and left hind-limb from the same animal. (B) Extensor digitorum longus
(EDL) muscles in draggen mice also took longer to reach both Tmax and T1/2R than wild-type (Tmax: Scn4a
+/+ = 15.9ms;
Scn4a
Dgn/+ = 20.0ms; P50.001. T1/2R: Scn4a
+/+ = 10.7ms; Scn4a
Dgn/+ = 17.3ms; P50.001). Single twitch force was also determined
for extensor digitorum longus muscles, with wild-type muscles exerting more force than draggen muscles (Scn4a
+/+ = 16.7g;
Scn4a
Dgn/+ = 9.8g; P50.001). (C) Extensor digitorum longus tetanic force generated by draggen mice (45.8) is reduced compared to
wild-type littermates (60.5) (P=0.003). (D) Representative traces of tetanic tension from wild-type and draggen extensor digitorum
longus muscles. The fatigue index (FI) is increased for draggen muscle (0.48) when compared to wild-type (0.25) (P50.001). (E) High
potassium levels diminish force generated by extensor digitorum longus muscles of draggen mice ex vivo. Scn4a
+/+ (n=7); Scn4a
Dgn/+
(n=9) (P-values: 14min: P=0.017; 16–20min: P50.003). The force generated by extensor digitorum longus was measured every 2min
with muscles submerged in a bath with normal (4.75mM) and high (12mM) potassium concentrations for 10min in each condition. Data
are expressed as mean  SEM. *P50.05; **P50.01; ***P50.001.
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sor digitorum longus muscles of wild-type and draggen mice and
no signiﬁcant differences were observed (P=0.6, data not
shown), suggesting that the muscle weakness and fatigue charac-
teristics in draggen mice are not caused by denervation or axon/
motor unit dysfunction.
High extracellular potassium levels can
elicit muscle weakness in draggen
muscle
Periodic paralysis is characterized by attacks of muscle weakness,
which can be elicited in some patients by changes in extracellular
potassium levels (Moxley et al., 1989; Vicart et al., 2004;
Hayward et al., 2008). The effect of different potassium levels
in muscle force was therefore measured ex vivo in the extensor
digitorum longus from 60-week-old wild-type and draggen male
mice in the presence of low (2mM), normal (4.75mM) and high
(12mM) potassium levels. Wild-type extensor digitorum longus
muscles exerted similar maximal force in all conditions. In contrast,
in draggen extensor digitorum longus muscles high, but not low
(data not shown), potassium levels resulted in a signiﬁcant force
reduction (Fig. 3E). Hence, a degree of muscle weakness can be
elicited ex vivo by high potassium in draggen muscle.
Progressive myopathy in draggen mice
Some forms of periodic paralysis and myotonia have been asso-
ciated with muscle histopathological alterations as patients age
(Bradley et al., 1990; Plassart et al., 1994; Nagamitsu et al.,
2000; Schoser et al., 2007). Tibialis anterior, extensor digitorum
longus and soleus hind-limb muscles were therefore examined in
male mice at two stages: young (12 weeks of age) and aged (60
weeks of age). At 60 weeks of age, haematoxylin and eosin stain-
ing revealed an increased number of central nuclei and the pres-
ence of larger muscle ﬁbres in aged draggen tibialis anterior
muscles compared to wild-type (Fig. 4A and B), providing
evidence of a progressive damage/regeneration process.
Interestingly, the soleus muscle was unaffected (data not
shown). NADH-tetrazolium reductase (NADH-TR) staining of the
tibialis anterior muscle at 60 weeks of age showed a ﬁbre switch
towards a more oxidative type together with ﬁbre grouping, par-
ticularly in the more oxidative tibialis anterior core (Fig. 4C and D).
Both the low oxidative ﬁbres in the cortex and the highly oxidative
ﬁbres in the tibialis anterior core were signiﬁcantly enlarged in
aged draggen mice (Fig. 4E). Young (12 weeks of age) draggen
tibialis anterior muscles did not have central nuclei (data not
shown). Muscle myosin heavy chain (MHC) immunostaining was
performed on young tibialis anterior muscle to quantify ﬁbre
types. Interestingly, at this stage there is already a signiﬁcant
degree of ﬁbre switching towards a more oxidative type in drag-
gen tibialis anterior muscle, in both males and females, regardless
of whether they have presented with dragging attacks (Fig. 4F
and G).
Transmission electron microscopy analysis of the tibialis anterior
muscle of two aged draggen and control male mice at 1.5 years
of age was carried out. Representative observations from two
draggen mice are shown in Fig. 5. The presence of tubular aggre-
gates (Fig. 5A) as well as irregular triads (Fig. 5B and C) was
revealed in ultrathin longitudinal sections (70nm). Triads of irregu-
lar size and orientation were widespread in many ﬁbres that did
not show tubular aggregates. There is some evidence of continuity
of the terminal cisternae of the triads with the large vesicles found
in the proximity of tubular aggregates (Fig. 5D), in agreement
with previous observations showing that tubular aggregates may
originate from the sarcoplasmic reticulum (Engel et al., 1970;
Schiafﬁno, 2012). None of these hallmarks were detected in the
age and sex-matched control sample (Fig. 5E and F). Thus, drag-
gen mice show progressive muscle pathology, mimicking the
muscle pathology seen in some myotonia and patients with peri-
odic paralysis (Bradley et al., 1990; Tengan et al., 1994; Feng
et al., 2009, 2011; Luan et al., 2009; Trip et al., 2009).
Metabolic abnormalities in draggen
mice
Male draggen mice, but not females, showed signiﬁcantly reduced
weight gain from 12 weeks of age compared to wild-type litter-
mates (Fig. 6A and Supplementary Fig. 5A). The weight differ-
ences in males were not due to differences in body size,
measured via femoral bone X-ray, or in food consumption, mea-
sured on a 24-h cycle (data not shown). Importantly, similar re-
sults were obtained when comparing the weights of wild-type and
Scn4a
M1592V/+ male mice (Supplementary Fig. 5B). To further dis-
sect differences in body composition, the amount of fat and lean
mass was measured using Echo-MRI at 18 weeks of age. Draggen
male mice displayed less total fat mass than their wild-type litter-
mates (Fig. 6B; P=0.015). As draggen male mice have less fat
mass yet consume similar amounts of food as wild-type litter-
mates, their whole body energy expenditure was measured.
Draggen mice had signiﬁcantly higher whole body energy expend-
iture than wild-type littermates when we controlled for total body
weight in the dark period of a 24h cycle (Fig. 6C, P=0.01).
Weight differences might also be explained by differences in cir-
culating leptin levels (Oswal and Yeo, 2010). We found a trend
towards a reduction in serum leptin levels in draggen mice com-
pared to wild-type at 40 weeks of age (Supplementary Fig. 5C,
P=0.07). We also tested glucose metabolism and found that
draggen mice re-established plasma glucose levels more efﬁciently
than wild-type littermates following a glucose tolerance test
(Fig. 6D), despite similar baseline insulin levels (Supplementary
Fig. 5D). In summary, mutations in the muscle speciﬁc Scn4a
gene have profound effects on the general metabolic status of
the whole animal.
AMPK is constitutively activated in
draggen and Scn4a
M1592V/+ skeletal
muscle in mice with hind-limb
immobility
As muscle is a major contributor to the whole body energy ex-
penditure and metabolic rate, we speculated that the systemic
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disturbed muscle energy demand that is required to re-establish
ion balance in myotonic muscle or after intermittent immobility
attacks. Muscle contractions increase the rate of ATP hydrolysis
which, via increases in the concentrations of AMP and ADP, acti-
vates the key intracellular energy sensor AMPK (Winder and
Hardie, 1996; Friedrichsen et al., 2013), mainly via phosphoryl-
ation of Thr172 (Hawley et al., 1996; Mu et al., 2001). We there-
fore hypothesized that the metabolic alterations seen in draggen
male mice may be mediated by differential AMPK activation in
mutant muscles. To estimate AMPK activation, Thr172 phosphor-
ylation was measured from tibialis anterior muscle in wild-type and
draggen male mice at two ages: young (12 weeks) and aged (60
weeks). Total AMPK levels were similar between all genotypes at
both ages. However, when compared to wild-type littermates,
AMPK Thr172 phosphorylation was higher in both young and
aged tibialis anterior muscles of draggen mice that have shown
at least one immobility episode (Fig. 7A). Moreover, AMPK acti-
vation levels were also higher in the tibialis anterior of the
Scn4a
M1592V/+ mice (Fig. 7B), which also showed intermittent
Figure 4 Progressive myopathy in draggen mice. (A) Pathological assessment of tibialis anterior (TA) muscle of 60-week-old male wild-
type and draggen littermates. Haematoxylin and eosin (H&E) of the tibialis anterior cortex shows central nuclei and hypertrophic muscle
ﬁbres in draggen muscle (delimited in yellow area to show the size of one draggen ﬁbre for comparison). Yellow arrows point to central
nuclei. (B) Quantiﬁcation of the central nuclei in the muscle ﬁbres of wild-type and draggen tibialis anterior muscles (n=3 mice per group,
n=3 ﬁelds per mouse; P=0.05). (C) NADH-TR activity staining shows more oxidative ﬁbre grouping in the core of the draggen tibialis
anterior muscles. (D) Higher magniﬁcation of the core of the tibialis anterior muscle stained with NADH-TH showing enlarged high
oxidative ﬁbre grouping in the draggen mice compare to the wild-type. (E) Quantiﬁcation of ﬁbre size (CSA, cross section area) in the
tibialis anterior core and cortex showing enlarged high and low oxidative draggen ﬁbres when compared to wild-type (n=3 per group,
P50.001 for both comparisons). (F) Representative MHC staining showing the ﬁbre type in the tibialis anterior muscle of 12-week-old
mice wild-type and draggen littermates (IIa ﬁbres in green and IIb ﬁbres in red). (G) Quantiﬁcation of the total number and the percentage
of IIa and IIb ﬁbres. (Scn4a
+/+ n=8; Scn4a
Dgn/+ n=6 mice, P=0.002 for both comparisons). Data are expressed as mean  SEM.
*P50.05; **P50.01. Scale bars: A =5 0mm; C and F = 500mm; D = 100mm.
A novel SCN4A mutation and mouse model Brain 2014: 137; 3171–3185 | 3179Figure 5 Tubular aggregates and vacuoles in skeletal muscle of draggen mice. Transmission electron microscopy analysis of the tibialis
anterior muscle from draggen (A–D) and control mice (E and F). (A) Representative view of single-walled tubular aggregates that have
accumulated between myoﬁbrils. (B) Longitudinal section showing triads of different morphological appearances (ﬁlled arrows). Note the
presence of densities between adjacent membranes (open arrows). (C) Detailed view of T tubules and sarcoplasmic reticulum of triads
(ﬁlled arrows) of irregular size and orientation. (D) Detailed view of a tubular aggregate region showing the continuity of the sarcoplasmic
reticulum from a presumed irregular triad (ﬁlled arrow) with a large vesicle (star). (E and F) Wide and detailed view, respectively, of triads
of normal size and orientation (arrows) from a control sample.
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steady-state activation of AMPK is not observed in draggen
mice that have not shown a hind-limb immobility episode using
our scoring system (Fig. 7C), despite all tested draggen mice
having underlying myotonia. Thus, higher activation levels of
AMPK may be a general feature of mouse models carrying
Scn4a mutations presenting with intermittent immobility attacks.
The higher basal levels of activated AMPK in draggen muscle
suggest a possible functional link between AMPK activation levels
and Nav1.4 channel physiology. We therefore investigated if
AMPK activation could directly modify the electrophysiology of
Nav1.4 channels in vitro. HEK293 cells transfected with Nav1.4
variants were incubated with the AMPK activator AICAR or
cotransfected with a constitutively active truncated AMPK clone
AMPK1(1–312). In these conditions, changes in AMPK activation
levels did not have any effects on voltage dependence of wild-
type or mutant Nav1.4 channel activation or fast inactivation
(Supplementary Fig. 6). Thus, at least in vitro, AMPK activation
is not sufﬁcient to signiﬁcantly alter the electrophysiology of the
Nav1.4 channel.
Blunted AMPK activation in draggen
muscles after in vivo stimulation
In patients, attacks of periodic paralysis can occur after physical
exertion, implying a potential link between energy demand and
paralysis episodes. To mimic exercise in the mice, we tetanically
stimulated the tibialis anterior and extensor digitorum longus mus-
cles of mice that have been previously used for the above in vivo
physiology recordings and measured AMPK activation levels.
Remarkably, muscles from draggen mice that had previously
shown immobility episodes were not able to activate AMPK to
the same degree as wild-type littermate controls after the tetanic
stimulation (Fig. 7D). Thus, AMPK activation is perturbed, both in
basal conditions and after stimulation in draggen muscles.
Figure 6 Draggen mutation affects body weight and metabolism. (A) Body weight (g) of male wild-type and draggen mice from 5 to 50
weeks of age. Draggen mice gain less weight than their littermate controls (P50.01 from 12 weeks; P50.001 from 18 weeks onwards).
At least 15 mice per genotype and time point were examined. (B) Body composition at 20 weeks of age in male mice. Draggen mice have
less total body weight [Scn4a
+/+ (n=24); Scn4a
Dgn/+ (n=17), P=0.006] due to a reduction in total fat mass (P=0.02), with no
changes in lean mass (P=0.65). (C) Whole body energy expenditure (KJ/h/kg) corrected by body weight (kg) shows draggen mice
exerting higher whole body energy expenditure in the dark period (P=0.01). Scn4a
+/+ (n=14); Scn4a
Dgn/+ (n=12). (D) Glucose
tolerance test curves during a 120-min intraperitoneal glucose injection (IPGTT) in 18-week-old male mice (n=15 per group; overall
P50.001; per individual time points: P50.001 at T30 and T60, and P=0.02 at ﬁnal time point T120). Data are expressed as
mean  SEM. *P50.05; **P50.01; ***P50.001; n.s. = not signiﬁcant.
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Here we report a novel pathological mutation in the SCN4A gene
in a patient presenting with myotonia and periodic paralysis. We
have also produced its mouse model, draggen, carrying the
equivalent point mutation in the mouse Scn4a gene. All tested
draggen mice had myotonia, and all draggen males and a subset
of draggen females also developed spontaneous hind-limb immo-
bility attacks. This is underlined by a progressive myopathy and
muscle ﬁbre switching towards a more oxidative type.
Figure 7 Changes in AMPK activation levels in mutant Scn4a hind-limb muscle. Immuno-blot analysis of mouse tibialis anterior muscle
lysates using antibodies to activated AMPK [Phospho-AMPK (Thr172) and total AMPK levels (1–2)]. AMPK activation is expressed as
the coefﬁcient between the p-AMPK/total-AMPK band intensities; graph values are relative to the average of each wild-type group.
Protein loading was controlled by GAPDH (data not shown). (A) Representative images of immunoblots from young (12-week-old) and
aged (60-week-old) wild-type or draggen mutant mice. In draggen mice the level of activated AMPK is higher than wild-type (n=6 per
genotype; P=0.02). (B) Representative images of immunoblots from tibialis anterior muscle of wild-type and Scn4a
M1592V/+ mice,
showing higher basal AMPK activation in Scn4a
M1592V/+ (n=4) when compared to wild-type (n=3); P=0.04. (C) Representative images
of immunoblots from wild-type and draggen littermates that have not shown a hind-limb dragging attack (NA) and draggen mice that
have already shown at least one immobility episode (A). AMPK activation is elevated only in draggen mice that have already shown
immobility attacks (n=4 per group; wild-type versus NA, P=0.4; wild-type versus A, P=0.03; A versus NA, P=0.04). (D) Representative
immunoblots of tetanically stimulated tibialis anterior and extensor digitorum longus muscles lysates from 60-week-old wild-type and
draggen littermates mice induced after in vivo physiology recordings (including muscle force, fatigue characteristics and estimation of
motor units). The quantiﬁcation graph shows blunted AMPK activation levels in draggen muscles after stimulation when compared to
wild-type (n=6 in both groups; P50.001). Data are expressed as mean  SEM. *P50.05; ***P50.001.
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alities, including diminished fat mass and improved glucose toler-
ance. This is accompanied by changes in AMPK activation, both in
basal conditions and after muscle stimulation, in mice that present
with dragging attacks.
The majority of dominant SCN4A causative mutations in peri-
odic paralysis with myotonia have been found in the pore forming
segments S5–S6 or the voltage sensor segment S4 of Nav1.4. The
mutation identiﬁed here is located in the transmembrane segment
S1 of domain II, where no other SCN4A mutations have been
previously described. There are other mutations in the homologous
S1 segment of domain IV of the Nav1.4 channel (Wagner et al.,
1997) presenting features of hyperkalaemic periodic paralysis and
paramyotonia congenita with reported gender differences. There
are also reported mutations in the homologous S1 residue of
domain I of the Nav1.4 channel (Petitprez et al., 2008), as well
as in another sodium voltage-gated paralogue (Nav1.7) (Cheng
et al., 2008) that cause similar effects to I588V, causing a hyper-
polarizing shift in the voltage dependence of activation. The
hyperpolarizing shift in the voltage dependence of activation
found in I588V Nav1.4 channels is found for several mutations
associated with myotonia (Petitprez et al., 2008; Kokunai et al.,
2012; Yoshinaga et al., 2012), and would lower the activation
channel threshold and contribute towards myotonia.
Depolarization caused by increased sodium channel activity and
the small enhancement of fast inactivation may contribute towards
reduced Nav1.4 channel availability and muscle weakness. Many
hyperkalaemic periodic paralysis mutations display attenuated slow
inactivation whereas the slow inactivation of I588V mutant chan-
nel was wild-type like. However, some hyperkalaemic periodic
paralysis mutations present with intact or increased slow inactiva-
tion (Hayward et al., 1999; Bendahhou et al., 2000), suggesting
that Nav1.4 mutations can lead to hyperkalaemic periodic paralysis
without disruption of slow inactivation.
We were able to elicit muscle weakness ex vivo in draggen
muscles by increasing the extracellular potassium concentration.
However, although highly statistically signiﬁcant, the drop in
muscle force (25%) in draggen muscle after increasing [K
+]
was less pronounced than the drop previously published in
Scn4a
M1592V/+ muscles; a drop in muscle force of 70% that
was conﬁrmed with our experimental set-up (data not shown).
This may correlate with the fact that in vitro these novel human
and draggen mutations had only small effects on voltage depend-
ence channel inactivation. Indeed, the intermittent attacks seen in
draggen mice are accompanied by high EMG activity, suggesting
that they are not produced by muscle weakness. Nevertheless, in
the patient described here, the I588V SCN4A mutation unequivo-
cally leads to myotonia and periodic paralysis.
Importantly, we report a progressive myopathy in draggen mice,
with the appearance of tubular aggregates, vacuoles and asso-
ciated muscle atrophy. Thus, it is not surprising to ﬁnd reduced
muscle force in aged draggen mice. Although we did not see any
tubular aggregates in our control muscles, it should be noted that
tubular aggregates have been previously reported in aged inbred
mice and could be a consequence of the ageing process (Agbulut
et al., 2000). However, similar pathological features have been
described in cases of periodic paralysis and myotonia
(Bradley et al., 1990; Schoser et al., 2007; Luan et al., 2009;
Feng et al., 2011). Therefore, draggen mice offer a novel excellent
model to study the role of tubular aggregates and vacuoles in the
pathophysiology of SCN4A channelopathies.
During the course of this investigation, we analysed
Scn4a
M1592V/+ mice that have previously been characterized but
were not reported to develop intermittent hind-limb dragging at-
tacks (Hayward et al., 2008). Using our scoring system, we were
able to detect hind-limb immobility attacks on Scn4a
M1592V/+
mice that were indistinguishable from those seen in draggen
mice (data not shown). The previous absence of reported immo-
bility attacks in Scn4a
M1592V/+ may be due to differences in the
genetic background between the strain used here and that used in
the initial characterization of the Scn4a
M1592V/+ mice (Hayward
et al., 2008).
The draggen mutation causes EMG myotonia in all tested drag-
gen males and females, indicating full penetrance of this pheno-
type. However, this is not the case for the intermittent immobility
events; the mutation affects all males, but only a subset of mutant
females. These sex differences are not explained by differences in
Scn4a allelic expression levels between males and females (data
not shown). This suggests that modifying factors differing be-
tween males and females, other than the mutation itself, may
have an impact on the biophysics of the mutant Nav1.4 channel,
making males more prone to suffer from immobility attacks. Sex
differences in phenotypic penetrance have been previously re-
ported in forms of periodic paralysis (Wagner et al., 1997; Kim
et al., 2004; Li et al., 2012; Ke et al., 2013) and in a mouse model
of hypokalaemic periodic paralysis (Wu et al., 2011). The identi-
ﬁcation of these potential sex-speciﬁc modulating factors could
make them attractive targets for therapeutic intervention.
To investigate possible factors that might modify the properties
of the mutant Nav1.4 channel, we looked into the whole body
metabolism of draggen mice. Lower body weight in draggen
males was accompanied by general metabolic alterations, including
enhanced whole body energy expenditure and glucose tolerance,
which together potentially contribute to the leaner phenotype.
Importantly, we also observed weight differences between
Scn4a
M1592V/+ and wild-type males. Overall, these data show
that mutations in the muscle speciﬁc Scn4a gene can produce
systemic metabolic alterations.
We hypothesized that the leaner phenotype seen in draggen
males could reﬂect differences in energy homeostasis. Indeed,
basal AMPK activation levels are higher in draggen muscles that
have shown at least one episode of hind-limb dragging. This could
potentially explain the glucose tolerance (Friedrichsen et al., 2013)
as well as the higher energy expenditure phenotypes in draggen
males. However, AMPK activation was not signiﬁcantly increased
in draggen muscle before showing at least an immobility episode
reported using our scoring system. This suggests that myotonia
alone may not be sufﬁcient to drive the increase in steady-state
AMPK activation levels. However, the severity of myotonia may
vary between individual draggen mice; in this scenario, mice with
the more severe myotonia could have more involuntary contractile
activity, presented as episodes of immobility, leading to a deple-
tion of energy and a subsequent activation of AMPK. This, in turn,
could result in endurance training-like adaptations such as blunted
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Interestingly, baseline AMPK activation levels were also higher in
Scn4a
M1592V/+ muscles, conﬁrming that the rise in AMPK activa-
tion levels is not unique to draggen muscles and could be a gen-
eralized feature of Scn4a mouse models showing myotonia and
hind-limb dragging attacks.
AMPK activation has been shown to affect the properties of ion
channels expressed in skeletal muscle such as Kir2.1 and KATP
channels (Alesutan et al., 2011; Yoshida et al., 2012), and
might couple changes in metabolism to cell excitability.
However, AMPK activation did not directly altered Nav1.4 channel
behaviour in vitro. A thorough investigation of the electrophysio-
logical properties of the muscle ﬁbres would be required to further
characterize the possible effects of AMPK activation on muscle
excitability.
In conclusion, we have identiﬁed a novel SCN4A mutation in a
human patient and created a mouse model carrying the equivalent
point mutation. Both mutations implicate a novel Nav1.4 domain
in the pathophysiology of myotonia and periodic paralysis. In
depth characterization validated the draggen mice as an excellent
new model to study the underlying muscle pathophysiology of the
human conditions, and uncovered novel systemic metabolic
abnormalities. These metabolic alterations are accompanied by
changes in muscle AMPK activation levels, suggesting a potential
role of the energy sensor AMPK in models of SCN4A
channelopathies.
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